Browse the corpus

Lipoid proteinosis is a rare autosomal recessive genodermatosis caused by loss-of-function mutations in the extracellular matrix 1 (ECM1) gene, resulting in hyaline-like material deposition within skin, mucosa, and other tissues. Clinical onset typically occurs in early childhood with a weak or hoarse cry from laryngeal involvement, followed by vesiculobullous or crusted cutaneous lesions that heal with pock-like or acneiform scarring. Progressive disease may produce thickened, waxy skin; oral mucosal infiltration with a cobblestone appearance; restricted tongue protrusion from frenular thickening; and moniliform blepharosis along the eyelid margins. Neurologic involvement may include seizures and neuropsychiatric manifestations, with characteristic mesial temporal lobe calcifications on neuroimaging. Airway compromise and spontaneous central nervous system hemorrhage represent severe complications. Diagnosis relies on clinicopathologic correlation, with confirmation by identification of a pathogenic ECM1 variant. Course content equips the participant to recognize hallmark cutaneous, mucosal, and neurologic features; construct a symptom-based differential diagnosis; and select appropriate testing, including skin biopsy and genetic confirmation. Learner objectives include risk stratification for life-threatening manifestations, longitudinal monitoring strategies, and individualized management planning when no randomized trial–based standard of care exists. Evidence-informed options reviewed in the course include off-label systemic retinoids, short courses of systemic corticosteroids for vesiculobullous lesions, and procedural approaches for laryngeal disease and scarring, with attention to adverse effects and postoperative risks. Interprofessional collaboration among clinicians in dermatology, otolaryngology, neurology, psychiatry, dentistry, and medical genetics enhances outcomes through coordinated airway assessment, seizure management, ophthalmic and dental surveillance, symptom-directed interventions, and timely genetic counseling to support reproductive decision-making and family risk assessment. Objectives: Identify the most common clinical features of lipoid proteinosis. Assess for the possible life-threatening sequelae of lipoid proteinosis. Compare lipoid proteinosis to other infiltrative disorders.

Course content equips the participant to recognize hallmark cutaneous, mucosal, and neurologic features; construct a symptom-based differential diagnosis; and select appropriate testing, including skin biopsy and genetic confirmation. Learner objectives include risk stratification for life-threatening manifestations, longitudinal monitoring strategies, and individualized management planning when no randomized trial–based standard of care exists. Evidence-informed options reviewed in the course include off-label systemic retinoids, short courses of systemic corticosteroids for vesiculobullous lesions, and procedural approaches for laryngeal disease and scarring, with attention to adverse effects and postoperative risks. Interprofessional collaboration among clinicians in dermatology, otolaryngology, neurology, psychiatry, dentistry, and medical genetics enhances outcomes through coordinated airway assessment, seizure management, ophthalmic and dental surveillance, symptom-directed interventions, and timely genetic counseling to support reproductive decision-making and family risk assessment. Objectives: Identify the most common clinical features of lipoid proteinosis. Assess for the possible life-threatening sequelae of lipoid proteinosis. Compare lipoid proteinosis to other infiltrative disorders. Collaborate with other healthcare professionals to improve outcomes for patients with lipoid proteinosis. Access free multiple choice questions on this topic.

Erich Urbach and Camillo Wiethe, Austrian physicians, first described lipoid proteinosis in 1929.[1] Lipoid proteinosis is a rare genodermatosis characterized by the deposition of hyaline-like material in various tissues and organs. Lipoid proteinosis is associated with a variety of characteristic cutaneous and mucosal findings as well as several neurologic, psychiatric, and gastrointestinal manifestations.[2][3][4][5][6]

Lipoid proteinosis is caused by a homozygous or compound heterozygous loss-of-function mutations in the extracellular matrix-1 (ECM1) gene located on chromosome 1q21.[7][8][9] Several mutation types (eg, missense, nonsense, deletion) and affected exons (eg, 6 and 7) have been reported, leading to variable genotypes and phenotypes.[10] Novel mutations continue to be identified.[7][9] Because lipoid proteinosis is inherited in an autosomal recessive pattern, patients often have affected family members, and some are children of consanguineous unions. The ECM1 gene encodes glycoproteins essential for the integrity of basement membranes and extracellular matrices, skin adhesion, and protein-protein interactions.[11][12]

Lipoid proteinosis is extremely rare, with approximately 400 cases reported in the medical literature worldwide. Men and women are affected equally.[2] The Namaqualand region in South Africa has the largest population of individuals with lipoid proteinosis. These individuals share a common mutation, suggesting a founder effect.[8] There is also a higher incidence of lipoid proteinosis in countries with higher rates of consanguinity.[13][14][15]

ECM1 is a glycoprotein with multiple roles in skin structure and function. The ECM1 protein interacts with the basement membrane-specific heparan sulfate proteoglycan core protein perlecan, and other proteins important for extracellular matrix structure and tissue remodeling, including matrix metalloproteinase-9, fibulin-3, and laminin 332.[12][16][17] Furthermore, ultrastructural analysis of erosive lesions in a child with lipoid proteinosis revealed free-floating desmosomes and loss of connection between some desmosomes and keratinocytes, suggesting a possible role for ECM1 in the attachment of keratin filaments to desmosomes.[18] A splice variant of ECM1, ECM1b, is expressed in the stratum spinosum and granulosum, whereas the full-length ECM1a is more prevalent in the basal layer, suggesting that ECM1 contributes to keratinocyte differentiation.[19] Finally, ECM1 expression is reduced in individuals with chronic ultraviolet light exposure, signifying an additional role in the cutaneous stress response.[20] Extracutaneous functions of ECM1 include regulation of endochondral bone and cartilage formation, endothelial cell proliferation, and angiogenesis.[21] High levels of ECM1 expression have been associated with certain cancers.[22][23] Furthermore, mutations in the ECM1 gene compromise protein-protein interactions and disrupt tissue homeostasis.[10][11][18] Hyaline-like accumulation in various tissues explains many classic clinical findings, such as hoarseness and moniliform blepharosis.

Histologically, lipoid proteinosis is characterized by hyaline-like periodic acid–Schiff-positive, diastase-resistant deposits within the papillary dermis and at the dermal-epidermal junction.[24] Skin microvascular changes include reduplication of blood vessel walls, enlarged vessels, and loss of the dermal capillary loop network.[25][26][27] Immunolabeling can inform diagnosis, especially early in the disease course. Reduced ECM1 protein, in conjunction with characteristic clinical findings, should heighten suspicion of lipoid proteinosis.[28] Congo red staining can help differentiate lipoid proteinosis from amyloidosis, which is often included in the differential diagnosis.[24]

In almost all affected individuals, the earliest manifestation is a weak or hoarse cry in early life due to hyaline-like deposits on the vocal cords.[29][30] Hoarseness and severe dysphonia can develop and persist throughout life.[31] Deposits within the larynx can occasionally obstruct the airway.[5] Cutaneous abnormalities present early in the disease course, usually beginning with vesicles or bullae, especially on the face, that heal with prominent pock-like or acneiform scarring. (See Image. Early Cutaneous Findings of Lipoid Proteinosis.)[24][32] Over time, the skin may appear thickened and waxy, with a yellowish hue.[33] Other cutaneous manifestations include papules, nodules, and plaques on the face and lips, as well as verrucous and hyperkeratotic lesions at sites of trauma or friction.[33] Early clinical clues, including cutaneous buttock lesions, may predict a more severe clinical course with neurologic involvement.[34] Moniliform blepharosis, characterized by beaded papules along the eyelid margin, is a pathognomonic finding identified in about 50% of patients. (See Image. Moniliform Blepharosis.)[35] Obstruction of the punctum by hyaline-like material may lead to epiphora. Similarly, infiltration of the lacrimal glands may cause dry eyes. More severe ocular manifestations, such as glaucoma and uveitis, have been rarely reported.[36][37][38] Other notable features of lipoid proteinosis include infiltrative hyaline-like material throughout the mouth and upper aerodigestive tract. A cobblestone appearance of the oral mucosa, yellow lip nodules, lip eversion, vegetative lesions, and fissures at the lateral commissures can be seen in patients with extensive disease.[5][33] As a result of Stensen duct obstruction and secondary xerostomia, patients with lipoid proteinosis are prone to frequent upper respiratory tract infections, recurrent parotitis, and dental caries.[12][39][40] The submandibular gland can become similarly obstructed and inflamed. The tongue is often firm to palpation, with a shortened, thickened frenulum that restricts protrusion.[13]

Other notable features of lipoid proteinosis include infiltrative hyaline-like material throughout the mouth and upper aerodigestive tract. A cobblestone appearance of the oral mucosa, yellow lip nodules, lip eversion, vegetative lesions, and fissures at the lateral commissures can be seen in patients with extensive disease.[5][33] As a result of Stensen duct obstruction and secondary xerostomia, patients with lipoid proteinosis are prone to frequent upper respiratory tract infections, recurrent parotitis, and dental caries.[12][39][40] The submandibular gland can become similarly obstructed and inflamed. The tongue is often firm to palpation, with a shortened, thickened frenulum that restricts protrusion.[13] Neurologic manifestations of lipoid proteinosis can be severe, including epilepsy, dystonia, progressive neuropsychiatric disorders (eg, memory loss and other cognitive impairment, behavioral changes, hallucinations, schizophreniform illness), and spontaneous central nervous system hemorrhage.[4][41][42][43][44] Bilateral, symmetric, comma-shaped calcifications of the amygdala are a pathognomonic radiologic finding. Calcification has also been reported in the hippocampus, basal ganglia, parahippocampal gyrus, uncinate gyrus, striatum, pineal gland, and perirhinal and parietal cortices.[3][45][46] Calcifications develop slowly and are seen more frequently in patients with longer disease duration.[3] Results from one study of 10 patients with lipoid proteinosis showed that 6 had amygdaloid complex calcification and degeneration and 3 had decreased medial temporal lobe perfusion, suspicious for underlying calcification. However, despite these imaging findings, these 9 patients did not differ from healthy controls regarding cognitive tasks (eg, memory, attention, executive function); they differed in recognizing facial expressions, emotional processing, and odor-associative learning and recognition.[46] In findings from another analysis of 7 patients with intracranial calcifications, 4 had a seizure history, with onset in childhood or young adulthood.[41] Focal seizures were the most common seizure type, as demonstrated by video electroencephalography.

Results from one study of 10 patients with lipoid proteinosis showed that 6 had amygdaloid complex calcification and degeneration and 3 had decreased medial temporal lobe perfusion, suspicious for underlying calcification. However, despite these imaging findings, these 9 patients did not differ from healthy controls regarding cognitive tasks (eg, memory, attention, executive function); they differed in recognizing facial expressions, emotional processing, and odor-associative learning and recognition.[46] In findings from another analysis of 7 patients with intracranial calcifications, 4 had a seizure history, with onset in childhood or young adulthood.[41] Focal seizures were the most common seizure type, as demonstrated by video electroencephalography. Rare reports of hyaline-like deposits throughout the gastrointestinal tract have been described, some of which regressed over time.[47] One patient presented with acute gastrointestinal tract hemorrhage due to deposits within the small bowel.[6][47] Recently, a cross-sectional study of patients with lipoid proteinosis in Turkey found simple renal cysts in 68% of patients; however, the clinical significance of these cysts was unknown because renal function and biochemical parameters were within the reference range.[48]

Because lipoid proteinosis follows an autosomal recessive pattern of inheritance, patients should be asked about family members with similar symptoms and about consanguinity. Synthesis of family history, physical examination, and histopathologic findings often raises suspicion of lipoid proteinosis; however, a definitive diagnosis requires identification of an ECM1 mutation. Patients with characteristic dermatologic manifestations should undergo a skin biopsy of lesions to confirm deposition of hyaline-like material. An otolaryngologist should evaluate patients for airway involvement and potential obstruction. Similarly, patients with neurologic or neuropsychiatric symptoms should be evaluated by neurology and psychiatry. Neuroimaging may be necessary to identify intracranial calcifications and other involved brain regions. Other evaluations will depend on disease manifestations, but should include frequent dental, dermatologic, and ophthalmologic evaluations.

There have been no randomized clinical trials to establish a standard of care for lipoid proteinosis, and no Food and Drug Administration–approved treatments are available. Treatment plans should be individualized based on disease manifestations and the patient's preference for improved cosmetic outcomes. Off-label systemic retinoids, such as acitretin (0.5 mg/kg/d), can be effective in treating cutaneous and laryngeal manifestations of lipoid proteinosis.[49][50][51] However, some patients treated with acitretin who had improved voice quality had limited, if any, cutaneous improvement.[52][53] Short-term courses of systemic corticosteroids can be effective for vesiculobullous skin lesions and oral ulceration.[2] Based on limited case reports, evidence regarding the efficacy of long-term oral dimethyl sulfoxide for the treatment of cutaneous lesions and hoarseness is conflicting.[54][55] Findings from one case report demonstrated clinical improvement with the chelating agent D-penicillamine (600 mg daily).[56] For patients with vocal cord involvement and impaired phonation, microlaryngosurgery for excision of vocal cord deposits and carbon dioxide laser procedures can be quite successful.[57][58] However, there is a risk of postoperative granulation tissue formation, fibrosis, and the need for follow-up interventions. Accordingly, some authors recommend surgical intervention only when the airway is compromised. To minimize the appearance of scars and moniliform blepharosis, cosmetic procedures such as CO2 laser ablation, dermabrasion, cryotherapy, blepharoplasty, and erbium-doped yttrium aluminum garnet ablative laser have been employed, with varying efficacy.[59][60][61] More recently, techniques such as microwave treatments and plasma exeresis have been used successfully and safely.[62][63] Management of neurologic and psychiatric manifestations of lipoid proteinosis should be tailored to each patient. Antiepileptic medications can minimize seizure frequency and severity. Antipsychotic medications can help manage behavioral changes and psychosis.[4][42]

Differential diagnoses may differ between patients. Possible differential diagnoses can be stratified based on the presenting symptoms of lipoid proteinosis. Cutaneous Lesions Herpes simplex infection Impetigo Epidermolysis bullosa Erythropoietic protoporphyria Lichen myxedematosus Systemic amyloidosis Nodular localized cutaneous amyloidosis Colloid milium Hyalinosis Xanthomas Scleromyxedema Leprosy Hydroa vacciniforme Incontinentia pigmenti Hoarseness Laryngitis Laryngotracheitis Laryngotracheobronchitis Vocal cord nodules Gastroesophageal reflux disease Vocal cord polyps Laryngeal hemangiomas Laryngeal cysts Vocal cord paralysis Vocal cord hypertrophy Macroglossia Systemic amyloidosis Hypothyroidism (congenital) Myxedema Acromegaly Mesial Temporal Lobe Calcification Fahr disease Calcified glioma Raine syndrome Previous herpes encephalitis Dystonia

Lipoid proteinosis typically has a benign, slowly progressive course and is generally compatible with a normal lifespan. However, laryngeal involvement with respiratory obstruction and central nervous system complications can be life-threatening or impart substantial morbidity.

Lipoid proteinosis can present with a wide range of clinical manifestations due to hyaline deposition in the skin, mucosa, and various organs. Of the possible clinical complications, airway obstruction, seizures, and spontaneous central nervous system hemorrhage are the most severe. Hyaline deposition in the small bowel has also been linked to gastrointestinal tract bleeding. Complications of surgical intervention on the vocal cords or larynx include bleeding, infection, and vocal cord scarring, leading to a change in voice quality and a possible need for repeated interventions. CCertain patients may be taking systemic medication to manage their disease, such as acitretin, systemic corticosteroids, antipsychotics, antiepileptics, and dopamine-modifying agents. These medications can have a variety of drug-specific adverse effects.

An interdisciplinary approach is recommended for patients with lipoid proteinosis. Counseling will likely involve a dermatologist, an otolaryngologist, a neurologist, a psychiatrist, a dentist, and a geneticist, depending on disease manifestations. Like other autosomal recessive conditions, carrier testing and reproductive counseling should be offered to patients and their family members.

Patients with lipoid proteinosis and their families should be informed about available treatment options. Education should include the genetic basis of this condition to inform family planning. Clinicians should emphasize the importance of monitoring for potentially life-threatening complications, including airway obstruction, seizures, and central nervous system hemorrhage. Education should also include genetic counseling and a review of treatment options as well as the associated risks and adverse effects.

Lipoid proteinosis is a rare genetic disease caused by an autosomal recessive mutation in the ECM1 gene. Lipoid proteinosis typically presents in early childhood with a weak or hoarse cry. Children often develop crusted or vesicular lesions that heal with atrophic scarring. Other clinical features include moniliform blepharosis, inability to protrude the tongue, and seizures. Lipoid proteinosis requires interprofessional collaboration for optimal patient care. Patients with suspected lipoid proteinosis should undergo a comprehensive evaluation by multiple specialists, including a dermatologist, neurologist, psychiatrist, otolaryngologist, dentist, and geneticist, to assess the disease burden and evaluate for potential life-threatening manifestations. Patients’ symptoms and quality of life should be assessed frequently. Additionally, genetic counseling may help patients better understand their condition and its mode of inheritance.